Atjaunināt sīkdatņu piekrišanu

Psychopharmacology: A mental health professionals guide to commonly used medications [Mīkstie vāki]

4.00/5 (10 ratings by Goodreads)
  • Formāts: Paperback / softback, 192 pages, height x width x depth: 234x156x10 mm, weight: 299 g
  • Sērija : Nursing
  • Izdošanas datums: 03-Sep-2018
  • Izdevniecība: Critical Publishing Ltd
  • ISBN-10: 1912096048
  • ISBN-13: 9781912096046
Citas grāmatas par šo tēmu:
  • Mīkstie vāki
  • Cena: 28,70 €
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
Psychopharmacology: A mental health professionals guide to commonly used medicationsPalielināt
  • Formāts: Paperback / softback, 192 pages, height x width x depth: 234x156x10 mm, weight: 299 g
  • Sērija : Nursing
  • Izdošanas datums: 03-Sep-2018
  • Izdevniecība: Critical Publishing Ltd
  • ISBN-10: 1912096048
  • ISBN-13: 9781912096046
Citas grāmatas par šo tēmu:
Permanent link: https://www.kriso.lv/db/9781912096046.html
Keywords:
This concise and accessible text is suitable for all trainee and registered health professionals who require knowledge and understanding of drugs used in the treatment of mental health conditions for prescribing or administering purposes. Introductory material provides a background on psychotropic drugs, the etiology of mental illness, some of the commonly used drugs in practice and brief notes on common non-pharmacological interventional options. It also examines biochemical and neurodevelopmental theories and the link to the pathophysiology of mental illness as well as clinical decision making. The central chapters of the book provide comprehensive coverage of all the major medications used in mental health. Each focuses on a specific class of drug, detailing the most commonly used medicines, including side effects, average doses, contra-indications and clinical management interventions that may be required. At the end of each chapter a series of review questions enable readers to review their learning, and theory is clearly related to practice throughout.
Meet the author vi
Acknowledgements vii
Foreword viii
What the reviewers say x
Introduction 1(3)
The structure of this book
2(1)
Learning features
2(2)
1 Mental Illness
4(15)
1.1 Introduction
4(2)
1.2 Aetiology of mental illness
6(1)
1.3 Neurodevelopmental theories
7(4)
Neurons and neurotransmitters
7(4)
1.4 Clinical decision-making in practice and medicine management
11(8)
2 Drugs Used In Psychoses
19(42)
2.1 Introduction
19(1)
2.2 Mechanism of action
20(5)
Biochemical theories
20(3)
Typical antipsychotics (first-generation antipsychotics)
23(1)
Atypical antipsychotics (second-generation antipsychotics)
24(1)
2.3 Dose and administration
25(9)
Rapid tranquillisation
25(6)
Antipsychotic drugs in depot preparation
31(2)
Prescribing antipsychotic drugs to smokers
33(1)
2.4 Adverse effects and management
34(21)
Extrapyramidal side effects
34(6)
Anticholinergic drugs
40(1)
Non-extrapyramidal adverse effects of antipsychotic drugs
40(8)
Weight gain monitoring and management
48(5)
Obligatory monitoring for clozapine therapy
53(2)
Neuroleptic malignant syndrome
55(1)
2.5 Medication adherence in mental health settings
55(6)
3 Drugs Used In Depression
61(20)
3.1 Introduction
61(1)
3.2 Mechanism of action
62(1)
Monoamine theory of depression
62(1)
3.3 Dose and administration
63(6)
3.4 Adverse effects and management
69(8)
Tricyclic antidepressants
69(1)
Selective serotonin reuptake inhibitors
69(2)
Serotonin-noradrenaline reuptake inhibitors
71(1)
Tetracyclic (noradrenergic and specific serotonergic antidepressants)
72(1)
Aminoketone (bupropion)
73(1)
Monoamine oxidase inhibitors
74(2)
Serotonin syndrome
76(1)
3.5 Differences in therapeutic effects of antidepressants
77(4)
4 Drugs Used In Dementia
81(12)
4.1 Introduction
81(1)
4.2 Mechanism of action
82(1)
Acetylcholinesterase inhibitors
82(1)
4.3 Dose and administration
83(2)
4.4 Adverse effects and management
85(2)
Acetylcholinesterase inhibitors
85(1)
Polypharmacy in the older person
86(1)
Antipsychotic therapy in the care of the older person
86(1)
4.5 Memantine (NMDA receptor antagonist)
87(6)
Mechanism of action of memantine
87(1)
Concomitant use of cholinesterase inhibitors and memantine
87(1)
Adverse effects and management of memantine
88(5)
5 Drugs Used In Bipolar Disorders
93(22)
5.1 Introduction
93(3)
5.2 Mechanism of action
96(1)
5.3 Dose and administration
97(6)
Lithium
98(1)
Valproate
99(2)
Carbamazepine
101(1)
Lamotrigine
102(1)
5.4 Adverse effects, monitoring and management
103(12)
Lithium
103(4)
Valproate
107(2)
Carbamazepine
109(2)
Lamotrigine
111(4)
6 Drugs Used In Anxiety Disorders
115(18)
6.1 Introduction
115(2)
6.2 Mechanism of action
117(3)
Benzodiazepine hypnotics and anxiolytics
117(1)
Non-benzodiazepine hypnotics
117(1)
Non-benzodiazepine anxiolytics
118(2)
6.3 Dose and administration
120(2)
6.4 Adverse effects and management
122(11)
Adverse effects of benzodiazepines
122(1)
Withdrawal from benzodiazepines
123(1)
Risk of overdose with benzodiazepines
124(1)
Adverse effects of non-benzodiazepine hypnotics
125(4)
Adverse effects of non-benzodiazepine anxiolytics
129(4)
Appendix: Answers to chapter review questions 133(22)
Glossary 155(10)
References 165(12)
Index 177
Herbert Mwebe is a Lecturer in Mental Health in the School of Health and Education at Middlesex University. He has a special interest in psychopharmacology, adverse physical health effects associated with psychotropic and physical health outcomes of people suffering from severe mental illness. Within the Department of Mental Health, Herbert takes the lead on physical health for both undergraduate and postgraduate programmes as well as a module leader for the physical health modules and pre-registrations modules for third year BSc mental health nursing students





Prior to entering academia, Herbert worked in several settings providing mental health care to people with acute mental health illness; most recently in General Practice where Herbert led on a PMS + mental health project in City and Hackney, commissioned by NHS England. The project's focus was improving mental and physical health outcomes for people suffering from mental illness in primary care. With a key function of performance management, Herbert provided clinical support and advice to General practices to be able to meet the Quality Outcome Framework (QOF) health parameters for people with severe mental illness.





Herbert holds the following qualifications: DipHE, Adv.Dip, Pg Cert HE, B.Sc MHS, M.Sc. Public health and Health promotion, Independent Prescriber.